神经生物标记物市场规模、份额、成长分析、按类型、按应用、按最终用户、按地区 - 行业预测，2024-2031 年

2022年神经生物标记市场规模预计为61.3亿美元，预测期内（2024-2031年）复合年增长率为13.6%，从2023年的69.6亿美元增至2031年的193.1亿美元。至。

全球神经生物标记市场预计将大幅扩张，主要是由于阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的盛行率不断上升，以及对精确诊断工具的需求不断增加。世界老化和生活方式的改变正在增加这些疾病的盛行率，并增加了对有效诊断的需求，以便进行早期疗育和加强疾病管理。神经生物标记推动了向精准医疗和标靶治疗的转变，神经生物标记使医疗保健提供者能够根据个人的遗传和分子特征定制治疗方案，优化结果，同时最大限度地减少副作用，这进一步加速了对神经生物标记的需求。然而，由于神经系统疾病的复杂性，他们面临挑战，使可靠生物标记的识别和检验变得复杂。确定生物标记的敏感性、特异性和预测价值需要广泛的研究和临床试验，这通常会导致一个耗时且昂贵的过程。此外，研究人员和医疗保健专业人员必须仔细考虑与生物标记开发相关的监管和道德问题，例如确保患者隐私和知情同意。生物标记测定和资料解释缺乏标准化是另一个障碍，因为实验室技术的不一致可能会妨碍研究之间的可比较性。话虽如此，美国神经生物标记市场正处于稳健的轨道上，预计在接下来的预测期内将出现持续增长和充满希望的机会。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 技术分析
• 管道分析
• 渗透率和成长前景分析
• PESTEL分析
• 专利分析

神经生物标誌物市场：按类型

• 市场概况
• 基因组
• 蛋白质体
• 代谢体学
• 影像
• 其他的

神经生物标记市场：依应用分类

• 市场概况
• 阿兹海默症
• 帕金森氏症
• 多发性硬化症
• 泛自闭症障碍
• 其他的

神经生物标记市场：依最终用户分类

• 市场概况
• 医院和医院实验室
• 独立临床诊断中心
• 研究机构等

神经生物标记市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Quanterix Corporation
• Thermo Fisher Scientific Inc.
• Myriad Genetics, Inc.
• QIAGEN NV
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Bio-Techne Corporation
• Alector Inc.
• bioMerieux
• Charles River Laboratories International, Inc.
• Cisbio
• C2N Diagnostics
• ImmunArray
• Euroimmun AG
• Abbott Laboratories

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The global neurological biomarkers market is poised for significant expansion, driven primarily by the rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, alongside an increasing demand for precise diagnostic tools. The aging global population and lifestyle factors have resulted in a surge of these conditions, fueling the need for effective diagnostics that enable early intervention and enhanced disease management. The shift towards precision medicine and targeted therapies further accelerates the demand for neurological biomarkers, which allow healthcare providers to tailor treatments based on individual genetic and molecular profiles, thereby optimizing outcomes while minimizing adverse effects. However, the market confronts challenges stemming from the intricate nature of neurological diseases, which complicates the identification and validation of reliable biomarkers. Extensive research and clinical trials are necessary to determine the sensitivity, specificity, and predictive value of biomarkers, often leading to time-consuming and costly processes. Additionally, regulatory and ethical challenges related to biomarker development, such as ensuring patient privacy and informed consent, need careful consideration from both researchers and healthcare professionals. The lack of standardization in biomarker assays and data interpretation presents another hurdle, as inconsistencies in laboratory techniques can hinder comparability across studies. Nevertheless, with a robust market trajectory, the US neurological biomarkers sector is expected to witness sustainable growth and promising opportunities in the forthcoming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segmental Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

The rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, serves as a critical market driver for the global neurological biomarkers market. With the aging population and lifestyle factors contributing to the surge in these conditions, there is an escalating demand for accurate, early diagnostic tools that can facilitate timely intervention and improve patient outcomes. Neurological biomarkers play a vital role in enhancing disease detection, monitoring progression, and evaluating treatment efficacy. As healthcare providers and researchers increasingly recognize the importance of personalized medicine, the need for innovative biomarkers to support tailored therapeutic approaches further propels market growth in this sector.

Restraints in the Neurological Biomarkers Market

One of the significant market restraints for the neurological biomarkers industry is the extensive and resource-intensive process required for their discovery and validation. This involves conducting comprehensive research and lengthy clinical trials that not only demand substantial financial investment but also extended timelines, which can impede the speed of bringing these innovations to market. Consequently, the high costs associated with the development and validation of biomarkers can limit access to these advanced diagnostic and therapeutic options, making them less affordable for healthcare providers and patients alike. This financial barrier may hinder the widespread adoption of neurological biomarkers in clinical practice, ultimately affecting market growth.

Market Trends of the Neurological Biomarkers Market

The Neurological Biomarkers market is witnessing a significant trend towards the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies, which are revolutionizing biomarker research and data analysis. This shift enables the automation of data interpretation, thereby streamlining the identification of critical patterns and facilitating accurate predictions of disease outcomes. As a result, the efficiency and precision in the discovery and validation of neurological biomarkers are markedly improved. The increasing adoption of AI and ML not only accelerates research timelines but also enhances the overall reliability of diagnostics, reflecting a transformative movement that is poised to redefine approaches to neurological disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Penetration and Growth Prospects Analysis
• PESTEL Analysis
• Patent Analysis

Neurological Biomarkers Market, By Type

• Market Overview
• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarkers Market, By Application

• Market Overview
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarkers Market, By End User

• Market Overview
• Hospital & Hospital Laboratories
• Independent clinical diagnostic centers
• Research Organizations and Others

Neurological Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cisbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C2N Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunArray
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroimmun AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments